Evidence map›Paper›PMID 25205565›Full record

ArticleCurrent protocols in chemical biology2014

A biocompatible "split luciferin" reaction and its application for non-invasive bioluminescent imaging of protease activity in living animals.

Aurélien Godinat, Ghyslain Budin, Alma R Morales, Hyo Min Park, Laura E Sanman, Matthew Bogyo, Allen Yu, Andreas Stahl, Elena A Dubikovskaya

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current protocols in chemical biology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Imaging Proteolytic Activities in Mouse Models of Cancer.Methods in molecular biology (Clifton, N.J.) · 2018
    Article
  5. Article
  6. Economical and scalable synthesis of 6-amino-2-cyanobenzothiazole.Beilstein journal of organic chemistry · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Aurélien GodinatInstitute of Chemical Sciences and Engineering, Swiss Federal Institute of Technology of Lausanne, Lausanne, Switzerland.
Ghyslain BudinInstitute of Chemical Sciences and Engineering, Swiss Federal Institute of Technology of Lausanne, Lausanne, Switzerland.
Alma R MoralesInstitute of Chemical Sciences and Engineering, Swiss Federal Institute of Technology of Lausanne, Lausanne, Switzerland.
Hyo Min ParkDepartment of Nutritional Science and Toxicology, University of California Berkeley, Berkeley, California.
Laura E SanmanDepartment of Chemical and Systems Biology, Stanford University School of Medicine, Stanford, California.
Matthew BogyoDepartment of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California.
Allen YuDepartment of Nutritional Science and Toxicology, University of California Berkeley, Berkeley, California.
Andreas StahlDepartment of Nutritional Science and Toxicology, University of California Berkeley, Berkeley, California.
Elena A DubikovskayaInstitute of Chemical Sciences and Engineering, Swiss Federal Institute of Technology of Lausanne, Lausanne, Switzerland.
École Polytechnique Fédérale de Lausanne · CHUniversity of California, Berkeley · USStanford University · US

Funding

Small Molecule Imaging of Protease ActivityR01EB005011 · NIBIB · STANFORD UNIVERSITY · PI BOGYO, MATTHEW · 2005 to 2013
$3.0M
Molecular Physiology of Liver Fatty Acid TransportersR01DK066336 · NIDDK · UNIVERSITY OF CALIFORNIA BERKELEY · PI STAHL, ANDREAS · 2004 to 2013
$2.7M
DEPENDENCE OF THERMOGENESIS AND BROWN ADIPOSE TISSUE FUNCTION ON FATP1 AND CD36R01DK089202 · NIDDK · UNIVERSITY OF CALIFORNIA BERKELEY · PI STAHL, ANDREAS · 2011 to 2015
$1.9M
NIBIB NIH HHS R01 EB005011NIBIB NIH HHS R01EB05011NIDDK NIH HHS R01 DK066336NIDDK NIH HHS R01DK066336-08NIDDK NIH HHS R01 DK089202NIDDK NIH HHS R01DK089202-01A1
6 · The paper itself

Abstract

The great complexity of many human pathologies, such as cancer, diabetes, and neurodegenerative diseases, requires new tools for studies of biological processes on the whole organism level. The discovery of novel biocompatible reactions has tremendously advanced our understanding of basic biology; however, no efficient tools exist for real-time non-invasive imaging of many human proteases that play very important roles in multiple human disorders. We recently reported that the "split luciferin" biocompatible reaction represents a valuable tool for evaluation of protease activity directly in living animals using bioluminescence imaging (BLI). Since BLI is the most sensitive in vivo imaging modality known to date, this method can be widely applied for the evaluation of the activity of multiple proteases, as well as identification of their new peptide-specific substrates. In this unit, we describe several applications of this "split luciferin" reaction for quantification of protease activities in test tube assays and living animals.

Indexed as

AnimalsAnimals, Genetically ModifiedBenzothiazolesCaspase 3Caspase 7Disease Models, AnimalFluorescent DyesLuminescenceMiceMolecular ImagingPeptide HydrolasesThrombinBenzothiazolesCaspase 3Caspase 7D-luciferinFluorescent DyesPeptide HydrolasesThrombinbioluminescent imagingbioocompatible reactionin vivonon-invasiveprotease activity

Identifiers

PMID25205565
PMCPMC4219325
OpenAlexW1493751822

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.